Tricyclic SpiroLactams Kill Mycobacteria In Vitro and In Vivo by Inhibiting Type II NADH Dehydrogenases

Dam, Sushovan; Tangara, Salia; Hamela, Claire; Hattabi, Theo; Faïon, Léo; Carré, Paul; Antoine, Rudy; Herlédan, Adrien; Leroux, Florence; Piveteau, Catherine; Eveque, Maxime; Flipo, Marion; Déprez, Benoît; Kremer, Laurent; Willand, Nicolas; Villemagne, Baptiste; C. Hartkoorn, Ruben

doi:10.1021/acs.jmedchem.2c01493

Public

Tricyclic SpiroLactams Kill Mycobacteria In Vitro and In Vivo by Inhibiting Type II NADH Dehydrogenases

Published in Journal of Medicinal Chemistry • Dec 6, 2022

Authors:

Sushovan Dam

Salia Tangara

Claire Hamela

Abstract

High Resolution Image Download MS PowerPoint Slide It is critical that novel classes of antituberculosis drugs are developed to combat the increasing burden of infections by multidrug-resistant strains. To identify such a novel class of antibiotics, a chemical library of unique 3-D bioinspired molec...

Subject

Chemistry

Mycobacterium marinum

In vivo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!